Patents by Inventor Martin Holcik

Martin Holcik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnostic marker for interferon responsiveness in multiple sclerosis
    Patent number: 8021840
    Abstract: Disclosed is a method of determining interferon responsiveness in a patient suffering from multiple sclerosis. The method comprises determining an amount of a XAF-1 gene expression level in a blood sample, which is obtained from the patient undergoing interferon therapy. The amount of the XAF-1 gene expression level in the blood sample is then correlated with the responsiveness of the patient to the interferon.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: September 20, 2011
    Assignee: Dianovix, Inc.
    Inventors: Virender Bhan, Andrea Hebb, Martin Holcik, Robert G. Korneluk, Craig Moore, George Robertson
  • METHOD FOR DIFFERENTIATING BETWEEN MULTIPLE SCLEROSIS SUBTYPES
    Publication number: 20110136133
    Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 9, 2011
    Applicant: Dianovix, Inc.
    Inventors: Virender BHAN, John Gillard, Andrea Hebb, Martin Holcik, Robert G. Korneluk, George Robertson
  • Method for differentiating between multiple sclerosis subtypes
    Patent number: 7858309
    Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: December 28, 2010
    Assignee: Dianovix, Inc.
    Inventors: Virender Bhan, John W. Gillard, Andrea Hebb, Martin Holcik, Robert G. Korneluk, George Robertson
  • Method for differentiating between multiple sclerosis subtypes
    Publication number: 20080020388
    Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
    Type: Application
    Filed: February 6, 2007
    Publication date: January 24, 2008
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventors: Virender Bhan, John Gillard, Andrea Hebb, Martin Holcik, Robert Korneluk, George Robertson
  • Antisense IAP oligonucleotides and uses thereof
    Patent number: 7294713
    Abstract: The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: November 13, 2007
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Diagnostic marker for interferon responsiveness in multiple sclerosis
    Publication number: 20070218493
    Abstract: Disclosed is a method of determining interferon responsiveness in a patient suffering from multiple sclerosis. The method comprises determining an amount of a XAF-1 gene expression level in a blood sample, which is obtained from the patient undergoing interferon therapy. The amount of the XAF-1 gene expression level in the blood sample is then correlated with the responsiveness of the patient to the interferon.
    Type: Application
    Filed: March 5, 2007
    Publication date: September 20, 2007
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventors: Virender Bhan, Andrea Hebb, Martin Holcik, Robert Korneluk, Craig Moore, George Robertson
  • Antisense IAP oligonucleotides and uses thereof
    Publication number: 20070142316
    Abstract: The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 21, 2007
    Inventors: Robert Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Antisense IAP nucleobase oligomers and uses thereof
    Publication number: 20070135371
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: October 26, 2006
    Publication date: June 14, 2007
    Inventors: Eric LaCasse, Daniel McManus, Jon Durkin, Robert Korneluk, Martin Holcik
  • Antisense IAP oligonucleotides and uses thereof
    Publication number: 20070123481
    Abstract: The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: June 30, 2006
    Publication date: May 31, 2007
    Inventors: Robert Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Method for treating inflammatory disorders
    Publication number: 20060123501
    Abstract: The invention features a method of treating an inflammatory disorder, such as sepsis, in a subject. The method involves administering to the subject an antagonist of cIAP2 expression and/or function, so that the disorder is treated.
    Type: Application
    Filed: December 2, 2005
    Publication date: June 8, 2006
    Inventors: Robert Korneluk, Martin Holcik, Damiano Conte, Charles Lefebvre, Eric LaCasse
  • Antisense IAP oligonucleotides and uses thereof
    Publication number: 20040127694
    Abstract: The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: August 7, 2003
    Publication date: July 1, 2004
    Inventors: Robert G. Komeluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Antisense IAP nucleic acids and uses thereof
    Patent number: 6673917
    Abstract: The present invention feature antisense IAP nucleic acids and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: January 6, 2004
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • XIAP IRES and uses thereof
    Patent number: 6171821
    Abstract: The invention features purified nucleic acid encoding a novel internal ribosome entry site (IRES) sequence from the X-linked inhibitor of apoptosis (XIAP) gene. The invention also features methods for using the XIAP IRES to increase cap-independent translation of polypeptide coding sequences linked to the XIAP IRES, and methods for isolating compounds that modulate cap-independent translation.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: January 9, 2001
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Martin Holcik, Peter Liston
  • XIAP IRES and uses thereof
    Patent number: 6159709
    Abstract: The invention features purified nucleic acid encoding a novel internal ribosome entry site (IRES) sequence from the X-linked inhibitor of apoptosis (XIAP) gene. The invention also features methods for using the XIAP IRES to increase cap-independent translation of polypeptide coding sequences linked to the XIAP IRES, and methods for isolating compounds that modulate cap-independent translation.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: December 12, 2000
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Martin Holcik, Peter Liston